Livingstone has advised the shareholders of Lucien Ortscheit GmbH (“Ortscheit” or “The Company”) on the sale to Silver Investment Partners (“SIP”). Livingstone acted as exclusive financial advisor to Ortscheit.
Ortscheit is a leading pharmaceutical wholesaler specializing in unlicensed medicinal products. SIP is an independent investor for equity financing of medium-sized companies in Germany, Austria, and Switzerland. The terms of the transaction are undisclosed.
Founded in Saarbrücken in 1963, Ortscheit operates internationally, providing access to pharmaceutical products that are temporarily unavailable or not yet approved in the target country. The Company also offers comparative drugs for clinical studies. The supply of unlicensed medicines bridges the time delay in initial approvals or possible medicine shortages in certain markets. Such trading also enables therapies for rare disease patients if a particular drug is not yet approved in their country.
The transaction prepares the ground for an efficient succession process. The Kloos family, owners since 2002, will retain a minority stake in the Company. In the short term, Mr. Kloos will continue to be responsible for business operations as Managing Director. The company headquarters in Saarbrücken, as well as the team, will be retained. SIP will provide sustainable support so Ortscheit may focus on strategic initiatives to expand its market.
“I am very pleased we have found an entrepreneurial and long-term oriented partner in Silver Investment Partners with whom we can implement an orderly succession arrangement for Ortscheit and maintain the headquarters for our employees,” stated Kurt Kloos, Managing Director of Ortscheit. “Together, we have completely new growth perspectives and opportunities.”
“Ortscheit is a market leader in a continuously growing niche market,” said Philipp Amereller, Managing Partner of SIP. “We shall support the Company, using its strong starting position to develop new business areas and further expand existing markets and product range. We are also considering attractive add-on acquisitions at the domestic and international levels.”
Ralph Hagelgans, Partner at Livingstone Partners, adds, “We are pleased to have found a solution for all stakeholders, which combines an individually structured and short-term succession plan with a growth strategy in a highly interesting pharmaceutical wholesale sector.“